Without randomized, long-term studies on the use of GLP-1 RAs in a large sample size of HS patients with a wide range of ages, comorbidities, risk factors, and sexes and without any confounding factors, it is difficult to conclusively determine whether GLP-1 RAs are a definitive treatment for HS
Science2006 May 12;312(5775):927-30
Buyers who are considering GLP BodyGuard should ideally discuss it with their prescribing physician or a registered dietitian who works with GLP-1 patients
Such unregulated peptides have had low purity percentages, driven up poison control emergency calls, and been connected to some major adverse events and allergies
While the rare risk of medullary thyroid cancer requires a cautious approach for those with a specific family history, these medications offer a potentially transformative path for many who have struggled with weight for years